LUND, Sweden, Nov. 5, 2014 (GLOBE NEWSWIRE) -- Laquinimod
· Teva presented new clinical safety data in RRMS patients treated with laquinimod for two or more years at joint ACTRIMS-ECTRIMS meeting
· Teva initiated clinical studies with laquinimod in primary progressive MS (PPMS) and Huntington's disease
· The ongoing US pivotal clinical study CONCERTO is continuing according to plan. Results are expected in the first half of 2016
Tasquinimod
· The Phase III study 10TASQ10 is proceeding according to the original schedule and results are expected in the first half of 2015
ANYARA
· Only out-licensing activities are being conducted
Paquinimod (57-57)
· Only out-licensing activities are being conducted
ISI
· CD selection expected in 2015.
New share issue
· Rights issue totaling approximately SEK 225 million to be approved by the Extraordinary General Meeting on December 1, 2014
Financial summary
MSEK | July - Sept. | January - Sept. | Full Year | ||||
2014 | 2013 | 2014 | 2013 | 2013 | |||
Net sales | 2.6 | 107.0 | 7.5 | 111.9 | 116.0 | ||
Operating loss | -55.7 | 27.9 | -172.8 | -128.6 | -209.0 | ||
Loss for the period | -56.6 | 29.2 | -174.5 | -130.0 | -212.1 | ||
Loss per share (SEK) | -0.76 | 0.39 | -2.33 | -1.77 | -2.87 | ||
(before and after dilution) |
For further information, please contact:
Tomas Leanderson, President and CEO
Tel: +46 (0)46 19 20 95
Hans Kolam, CFO
Tel: +46 (0)46 19 20 44
Active Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 (0)46 19 20 00
Fax: +46 (0)46 19 11 00
The report is also available at www.activebiotech.com
Active Biotech AB Interim report January - September 2014 http://hugin.info/1002/R/1868647/656843.pdf
HUG#1868647